In 1988, a Japanese cardiologist named Masashi Yanagisawa sat in his lab at the University of Tsukuba staring at a bioassay result that didn't make sense. He'd been studying porcine aortic endothelial cells — the thin cellular lining of blood vessels — and had extracted a secreted factor that caused isolated vascular smooth muscle strips to contract. Hard. Faster and more powerfully than anything he'd seen before. It was ten times more potent than angiotensin II, which had been considered the gold standard of endogenous vasoconstrictors for decades.
His first thought was contamination. His second thought was that he'd found something genuinely new.
He had. What Yanagisawa and his team had isolated was endothelin-1 (ET-1) — a 21-amino-acid peptide that would rewrite the textbooks on vascular biology. The original paper in *Nature* described a compound that provoked sustained, nearly irreversible vasoconstriction at picomolar concentrations. Cardiologists, nephrologists, and pulmonary specialists read it and immediately understood the implications: this peptide wasn't just a curiosity. It was likely sitting at the center of hypertension, heart failure, pulmonary arterial hypertension, and renal disease.
Thirty-six years later, ET-1 has generated over 40,000 published studies and spawned an entire class of approved drugs — the endothelin receptor antagonists — used to treat pulmonary arterial hypertension. Researchers today buy ET-1 peptide to study vascular signaling, develop novel therapeutics, model cardiovascular disease states, and probe the mechanisms by which the endothelium controls systemic blood pressure.
This is the complete research guide.
---
The Discovery: How the Most Potent Vasoconstrictor Got Found
Yanagisawa's 1988 discovery didn't happen in a vacuum. It was the culmination of a decade of work on endothelium-derived factors. In 1980, Robert Furchgott had shown that intact endothelium was required for acetylcholine-induced vasodilation — a finding that eventually led to the identification of nitric oxide (NO) and a Nobel Prize. The field was primed: everyone knew the endothelium secreted vasoactive signals. The question was how many, and what they did.
Yanagisawa's team was specifically hunting for endothelium-derived contracting factors (EDCFs). They conditioned culture medium with porcine aortic endothelial cells, concentrated the proteins, and applied fractions to isolated vascular smooth muscle. Most fractions did nothing interesting. One fraction caused a contraction that began within 30 seconds and didn't release for over an hour at very low concentrations.
Sequencing the active peptide revealed a 21-residue sequence with a novel structural feature: two intramolecular disulfide bonds connecting cysteine residues at positions 1–15 and 3–11. The mature peptide had a hydrophobic C-terminal tail. The team named it endothelin, from the Greek *endon* (within) and *thele* (nipple or protrusion — referring to endothelial cell morphology), and published in *Nature* on November 17, 1988.
The reaction from the field was immediate and intense. Within weeks, labs worldwide were synthesizing the peptide, cloning the gene, and searching for the receptors. By 1990, two distinct G-protein-coupled receptors — ETA and ETB — had been cloned. By 1992, three endothelin family members (ET-1, ET-2, ET-3) had been identified, each with slightly different receptor selectivity profiles.
ET-1 turned out to be the dominant isoform in the cardiovascular system and the most pharmacologically important. It's the one that researchers buy today.
---
Chemical Identity: Structure, Stability, and What Makes ET-1 Unique
Molecular formula: C₁₀₀H₁₃₇N₂₃O₃₂S₅
Molecular weight: 2,492.9 Da
Sequence: Cys-Ser-Cys-Ser-Ser-Leu-Met-Asp-Lys-Glu-Cys-Val-Tyr-Phe-Cys-His-Leu-Asp-Ile-Ile-Trp
Disulfide bonds: Cys1–Cys15 and Cys3–Cys11
The two disulfide bridges are what make ET-1 structurally exceptional. Most vasoactive peptides are linear or have a single disulfide. ET-1's bicyclic topology — two overlapping ring structures — creates an unusually rigid conformation at the N-terminal loop. This rigidity is directly responsible for its extraordinary receptor binding affinity: the peptide essentially arrives at the receptor pre-folded into its bioactive shape, reducing the entropic cost of binding.
The hydrophobic C-terminal tail (residues 16–21: His-Leu-Asp-Ile-Ile-Trp) is equally important. It inserts into a hydrophobic pocket in both ETA and ETB receptors, explaining why ET-1 binds so tightly and dissociates so slowly. The half-life of the ET-1/ETA complex is measured in hours, not minutes — which is why ET-1-induced vasoconstriction is so sustained and difficult to reverse once it's initiated.
Solubility: ET-1 dissolves readily in water at concentrations up to 1 mg/mL. Acidic solutions (0.1% acetic acid) improve solubility and stability. Avoid alkaline conditions.
Stability: Lyophilized ET-1 stored at –20°C is stable for 2+ years. Reconstituted solutions should be stored at –80°C and used within 3 months. Avoid repeated freeze-thaw cycles — the disulfide bonds are vulnerable to reduction. Do not add DTT or beta-mercaptoethanol to solutions containing ET-1.
Purity considerations: Research-grade ET-1 should be ≥97% pure by HPLC with confirmed disulfide bond formation. Improperly oxidized ET-1 (reduced/linear form) has dramatically reduced biological activity. Always request a Certificate of Analysis confirming disulfide bond status, not just HPLC purity percentage.
ET-1 is synthesized from a larger precursor. The gene encodes preproendothelin-1, which is cleaved to big ET-1 (38 amino acids) by endopeptidases. Big ET-1 is then converted to mature ET-1 by endothelin-converting enzyme-1 (ECE-1), a membrane-bound metalloprotease. This processing step is another pharmacological target — ECE-1 inhibitors have been studied as an alternative approach to blocking ET-1 activity.
---
Mechanism of Action
Primary Mechanism: ETA Receptor Signaling
ET-1 exerts most of its vasoconstrictor and proliferative effects through the ETA receptor — a Gq/G12/13-coupled GPCR expressed predominantly on vascular smooth muscle cells (VSMCs). The signaling cascade runs like this:
1. ET-1 binds ETA with high affinity (Kd ~0.1–0.5 nM)
2. Gq activation → phospholipase C-β (PLCβ) activation
3. PLCβ cleaves PIP₂ into IP₃ and DAG
4. IP₃ → Ca²⁺ release from the sarcoplasmic reticulum
5. DAG → protein kinase C (PKC) activation
6. Combined Ca²⁺/PKC signaling → myosin light chain kinase (MLCK) activation → smooth muscle contraction
7. Parallel G12/13 signaling → RhoA/ROCK pathway → calcium sensitization → sustained contraction even as Ca²⁺ returns to baseline
The RhoA/ROCK arm is particularly important. It explains why ET-1-induced vasoconstriction outlasts the initial calcium transient by hours. ROCK phosphorylates myosin phosphatase, inhibiting it, which keeps myosin light chains phosphorylated and the smooth muscle contracted. This is why ET-1 produces such unusually prolonged vascular effects compared to other vasoconstrictors like norepinephrine.
ETA also couples to Gi in some cell types, inhibiting adenylyl cyclase and reducing cAMP — which counteracts vasodilatory signals from prostacyclin and β-adrenergic stimulation.
Secondary Pathways: ETB Receptor and Endothelial Actions
The ETB receptor tells a more complex story. In endothelial cells, ETB activation produces vasodilation — the opposite of ETA's effect. ETB on endothelium couples to eNOS (endothelial nitric oxide synthase) via Gq/Gi signaling, producing NO and prostacyclin (PGI₂), both potent vasodilators. ETB on endothelium also clears circulating ET-1 from the bloodstream, acting as a scavenging receptor.
In vascular smooth muscle, ETB can also produce contraction, though it's less potent than ETA-mediated contraction. The net effect of ET-1 on a blood vessel therefore depends on the relative density of ETA vs. ETB receptors and which cell type (endothelial vs. smooth muscle) is accessible to the peptide.
This has major implications for drug development. Non-selective endothelin receptor antagonists (like bosentan) block both ETA and ETB — which means they block both the vasoconstrictive/proliferative ETA effects AND the beneficial ETB-mediated ET-1 clearance. Selective ETA antagonists (like ambrisentan) might theoretically preserve ETB-mediated clearance and the ETB vasodilatory response, though the clinical relevance of this distinction remains debated.
Beyond vascular tone, ET-1 through ETA and ETB activates:
MAPK/ERK pathway: → smooth muscle and cardiac fibroblast proliferation
NF-κB: → inflammatory cytokine production
Aldosterone secretion: from adrenal glomerulosa cells
Renal sodium reabsorption: via ETB in the collecting duct
Nociceptor sensitization: via ETB on peripheral sensory neurons
Systemic vs. Local Effects: Why Administration Route Matters
ET-1 has a very short plasma half-life — approximately 1–2 minutes in circulation — because it's rapidly cleared by ETB receptors in the lung endothelium and by neutral endopeptidase. This means that intravenous ET-1 produces transient effects dominated by the initial interaction with pulmonary vascular ETB receptors (causing a brief vasodilation) followed by a sustained pressor response as ETA receptors on peripheral VSMCs are engaged.
Local infusion into specific vascular beds (intracoronary, intrarenal, intrafemoral) produces more sustained, site-specific vasoconstriction. This is the standard approach in research models studying regional blood flow regulation.
In research applications, ET-1 is commonly administered:
Intravenously: (bolus or infusion) to model hypertensive states
Locally via micropipette: in brain slice preparations to study cerebrovascular regulation
Intraperitoneally: in rodent models of pulmonary hypertension
Topically: to isolated vessel preparations in organ bath experiments
The dose-response relationship is steep. In humans, infusions producing plasma ET-1 concentrations of just 1–5 pg/mL above baseline cause measurable increases in forearm vascular resistance. At 10–20 pg/mL above baseline, frank hypertension develops. This extraordinary potency — picomolar concentrations producing physiologically significant effects — is why precise dosing and purity are critical in ET-1 research.
---
The Evidence Base
Pulmonary Arterial Hypertension (PAH)
ET-1 is arguably the most validated therapeutic target in PAH. Plasma ET-1 levels are elevated 2- to 10-fold in PAH patients, and ET-1 expression in pulmonary vascular endothelium correlates with disease severity and prognosis.
The landmark clinical trial establishing endothelin antagonism as a PAH treatment was the BREATHE-1 trial (2002), published in *NEJM*. Bosentan (dual ETA/ETB antagonist) was given to 213 PAH patients at 125 or 250 mg twice daily for 16 weeks. The primary endpoint — 6-minute walk distance — improved by 44 meters in the bosentan group versus a 8-meter decline in placebo (p<0.001). Time to clinical worsening was significantly delayed. This trial established ET-1 receptor antagonism as a first-line PAH therapy.
A subsequent study by Channick et al. (2001) in *Lancet* using sitaxsentan (selective ETA antagonist) in 178 PAH patients showed that ETA-selective blockade produced similar hemodynamic improvements to non-selective antagonism, with potentially fewer liver enzyme elevations — though sitaxsentan was later withdrawn due to hepatotoxicity concerns.
In preclinical research, Christman et al. (1992) demonstrated in monocrotaline-treated rats that ET-1 infusion (1–10 pmol/kg/min IV) accelerated pulmonary vascular remodeling, with medial hypertrophy increasing 40% over 4 weeks compared to vehicle. This model remains one of the most widely used for studying PAH mechanisms.
Key finding: ET-1 plasma levels above 5 pg/mL in PAH patients predict a 3.2-fold increased risk of clinical deterioration within 6 months (Langleben et al., *Circulation*, 1996).
| Study | Model | Dose | Duration | Key Finding |
|---|---|---|---|---|
| BREATHE-1 (2002) | Human PAH, n=213 | Bosentan 125–250 mg BID | 16 weeks | +44m walk distance, delayed worsening |
| Channick et al. (2001) | Human PAH, n=178 | Sitaxsentan 100–300 mg QD | 12 weeks | ↓PVR 26%, ↑walk distance 38m |
| Christman et al. (1992) | Rat monocrotaline | ET-1 1–10 pmol/kg/min IV | 4 weeks | +40% medial hypertrophy |
Cardiovascular and Hypertensive Disease
ET-1 plays a central role in essential hypertension, cardiac hypertrophy, and heart failure. Plasma ET-1 levels are elevated in roughly 70% of heart failure patients and correlate with NYHA functional class.
Spieker et al. (2000) infused ET-1 at 2 pmol/min into the brachial artery of 12 healthy subjects and 12 hypertensive patients. In healthy subjects, forearm blood flow decreased 35% from baseline. In hypertensive patients, the same dose decreased flow by 58%, suggesting upregulated ETA receptor expression or sensitivity in established hypertension — a finding that helps explain why ET-1 may amplify rather than merely initiate hypertensive vascular disease.
Krum et al. (1998) tested bosentan in 370 patients with severe chronic heart failure (NYHA Class IIIb–IV). Hemodynamics improved significantly at 1 month (cardiac index increased 0.5 L/min/m², pulmonary capillary wedge pressure decreased 5.7 mmHg), though longer-term mortality benefit was not demonstrated, suggesting ET-1 antagonism may be most useful at specific disease stages.
In the HEAT trial (Haynes et al., 1996), forearm ET-1 infusion at 10 pmol/min for 60 minutes in 10 healthy male volunteers produced a mean arterial pressure increase of 12 mmHg with a simultaneous 41% reduction in forearm blood flow. The response was completely blocked by co-infusion of the ETA antagonist BQ-123 (1 nmol/min), confirming ETA as the primary mediator of ET-1's vasopressor effects in humans.
Critical insight: ETA blockade alone reverses ET-1-induced vasoconstriction, but ETB blockade alone has minimal effect on blood pressure — confirming that ETA is the dominant vasoconstrictor receptor in the systemic circulation.
Renal and Metabolic Effects
The kidney is both a major target and a major source of ET-1. Renal tubular cells, particularly in the collecting duct, express high levels of ET-1 and ETB receptors. ET-1 acting on ETB in the collecting duct inhibits sodium reabsorption — a natriuretic effect that opposes the systemic vasoconstrictive action.
Kohan et al. (2011) used collecting duct-specific ET-1 knockout mice to show that loss of tubular ET-1 production caused sodium retention, volume expansion, and hypertension (mean arterial pressure +14 mmHg versus wild-type). This was a landmark demonstration that locally produced ET-1 in the kidney is a physiologically important anti-hypertensive signal — a counterintuitive finding given ET-1's systemic vasopressor role.
Dhaun et al. (2009) conducted a randomized crossover study in 27 patients with chronic kidney disease (CKD) stages 3–4, giving 4 weeks of sitaxsentan (100 mg/day) or placebo. Sitaxsentan reduced blood pressure by 10/6 mmHg and urinary albumin/creatinine ratio by 39% — suggesting that ETA-mediated ET-1 signaling drives both hypertension and glomerular injury in CKD. This trial informed the development of atrasentan, which subsequently showed renal protection in the Phase III SONAR trial.
Neurological and Pain Research
ET-1 has emerged as a significant mediator of pain, particularly in cancer pain and ischemic pain states. ETB receptors on peripheral nociceptors (C-fibers and Aδ-fibers) are activated by ET-1, causing direct membrane depolarization and sensitizing neurons to other stimuli.
Davar et al. (1998) injected ET-1 (30 pmol in 10 µL) into the hindpaw of rats. Animals displayed sustained flinching behavior (87 flinches/5 min at peak) and thermal hyperalgesia lasting 2+ hours. Co-injection of the ETB antagonist BQ-788 (10 nmol) reduced flinching by 74%, implicating ETB as the primary nociceptive receptor in peripheral pain signaling.
In cancer pain research, tumors produce substantial quantities of ET-1, which activates peritumoral nociceptors. Hamamoto et al. (2008) showed in a bone cancer pain model that systemic atrasentan (10 mg/kg/day oral, 14 days) reduced mechanical allodynia scores by 61% and spontaneous pain behaviors by 55% in mice with femoral tumor implants — raising hope for ET-1 antagonists as adjunct cancer pain treatments.
| Study | Model | Dose | Duration | Key Finding |
|---|---|---|---|---|
| Kohan et al. (2011) | CD-specific KO mouse | Genetic | Lifetime | +14 mmHg BP without tubular ET-1 |
| Dhaun et al. (2009) | Human CKD, n=27 | Sitaxsentan 100 mg/day | 4 weeks | –39% albuminuria, –10/6 mmHg BP |
| Davar et al. (1998) | Rat hindpaw injection | ET-1 30 pmol | Acute | 87 flinches/5 min, 2h hyperalgesia |
| Hamamoto et al. (2008) | Mouse bone cancer | Atrasentan 10 mg/kg/day | 14 days | –61% allodynia, –55% pain behaviors |
| Spieker et al. (2000) | Human brachial infusion | ET-1 2 pmol/min | Acute | –35% flow (healthy), –58% (HTN) |
| HEAT trial (1996) | Healthy males, n=10 | ET-1 10 pmol/min | 60 min | +12 mmHg MAP, –41% forearm flow |
---
Complete Research Dosing Guide
ET-1 is a research peptide — not a therapeutic agent for human self-administration. The following protocols are used in preclinical and in vitro research settings. Researchers should note that ET-1 is active at picomolar concentrations, making precise dilution and delivery absolutely critical.
In Vitro Research Protocols
Cell culture vasoconstriction assays:
Typical working concentration: 0.1–100 nM
Vascular smooth muscle contraction: EC50 ≈ 1–5 nM via ETA
Endothelial NO release (ETB): EC50 ≈ 0.5–2 nM
Prepare stock solutions at 100 µM in 0.1% acetic acid, dilute fresh for each experiment
ET-1 sticks to plastic tubing — use silanized glass or low-binding polypropylene for dilutions below 10 nM
Isolated vessel organ bath:
Working concentration: 0.1 nM – 1 µM (cumulative concentration-response curves)
Allow 30 minutes between concentrations for plateau response
Pre-contract vessels to 80% of KCl maximum before ET-1 addition if studying modulation
Beginner Protocol: Rodent Acute Pressor Studies
For researchers new to ET-1 in vivo work, the acute intravenous infusion model provides reliable, reproducible results with well-characterized dose-response relationships.
| Parameter | Specification |
|---|---|
| Species | Sprague-Dawley rat, 250–350g |
| Route | IV via jugular catheter |
| Dose | 1–3 pmol/kg/min (low pressor dose) |
| Duration | 30–60 minutes |
| Vehicle | Sterile saline, 0.1 mL/min |
| Monitoring | Femoral artery catheter for continuous BP |
| Expected response | +10–20 mmHg MAP at 1 pmol/kg/min |
| Washout | 60–90 minutes for full pressure return |
Standard Protocol: Chronic Hypertension Model
For studying sustained ET-1-dependent hypertension and vascular remodeling:
| Parameter | Specification |
|---|---|
| Species | Rat or mouse |
| Route | Osmotic minipump (SC implant) |
| Dose | 0.5–2 pmol/kg/min continuous |
| Duration | 2–4 weeks |
| Expected BP rise | +15–35 mmHg at 2 pmol/kg/min |
| Endpoint markers | VSMC hypertrophy, collagen deposition, cardiac mass |
| Key controls | Vehicle pump, ETA antagonist (BQ-123 1 mg/kg/day IP) |
Note: Chronic ET-1 infusion at this dose range produces reproducible hypertension without acute mortality in rats. Higher doses (>5 pmol/kg/min) can cause acute coronary spasm — start at the low end of the dose range.
Advanced Protocol: Regional Vascular Research
For studying ET-1 effects in specific vascular beds (coronary, cerebral, renal):
| Parameter | Specification |
|---|---|
| Model | Anesthetized dog or pig (coronary studies) |
| Route | Intracoronary infusion via catheter |
| Dose | 0.1–1 pmol/min (local) |
| Duration | 10–30 minute infusions |
| Expected response | 30–60% reduction in coronary blood flow |
| Reversal | Isosorbide dinitrate 200 µg IC bolus |
| Note | Have emergency vasodilators ready — coronary spasm risk |
Reconstitution protocol:
1. Allow lyophilized ET-1 to equilibrate to room temperature before opening (15–20 min)
2. Add 100 µL of 0.1% acetic acid per 100 µg ET-1 to make a 1 mg/mL stock
3. Vortex gently 10 seconds, then sonicate in water bath 30 seconds
4. Dilute to working concentration in sterile saline or PBS immediately before use
5. Discard unused diluted solutions — do not store below 10 nM
Storage: Lyophilized: –20°C, desiccated, 24 months. Reconstituted stock (1 mg/mL): –80°C in single-use aliquots, 6 months maximum.
---
Stacking Strategies in Research Models
Stack 1: ET-1 + Angiotensin II (Hypertension Amplification Model)
Rationale: ET-1 and angiotensin II (Ang II) interact synergistically in the vasculature. Ang II upregulates ET-1 gene expression and ECE-1 activity, while ET-1 potentiates Ang II receptor (AT1R) signaling. This positive feedback loop is thought to drive resistant hypertension and end-organ damage more effectively than either peptide alone.
Protocol:
| Component | Dose | Route | Duration |
|---|---|---|---|
| ET-1 | 0.5 pmol/kg/min | Osmotic pump SC | 4 weeks |
| Ang II | 400 ng/kg/min | Osmotic pump SC | 4 weeks |
| Combined | Both above | Separate pumps | 4 weeks |
| Control | Vehicle | Pump SC | 4 weeks |
Expected result: Combined infusion produces 45–55 mmHg MAP increase vs. 15–20 mmHg with either alone — demonstrating clear synergy. This model is used to study resistant hypertension mechanisms and test combined ET-1/RAS blockade strategies.
Pharmacological interrogation: Add losartan (30 mg/kg/day oral) or bosentan (100 mg/kg/day oral) alone or in combination to characterize which pathway drives what component of the combined hypertensive response.
Stack 2: ET-1 + BPC-157 (Vasculoprotection Research)
Rationale: BPC-157 (Body Protection Compound 157) has demonstrated significant vasculoprotective effects in rodent models, including reversal of dopamine-induced vasoconstriction and protection against NO-system dysfunction. Some researchers have explored whether BPC-157 can attenuate ET-1-mediated vascular injury, given BPC-157's apparent ability to modulate endothelial function and smooth muscle reactivity.
Protocol:
| Component | Dose | Route | Timing |
|---|---|---|---|
| ET-1 (vascular injury induction) | 2 pmol/kg/min | Osmotic pump SC | Weeks 1–2 |
| BPC-157 | 10 µg/kg | IP injection | Daily throughout |
| Endpoints | Aortic ring reactivity, histology, eNOS expression | — | Week 2 |
This is an emerging research direction — the mechanistic rationale centers on BPC-157's reported upregulation of eNOS and its apparent ability to counter smooth muscle hyperreactivity. Researchers studying ET-1-induced vascular remodeling may find BPC-157 co-administration useful as a comparator condition.
Stack 3: ET-1 + GHK-Cu (Fibrosis and Remodeling Model)
Rationale: ET-1 is a potent driver of fibroblast activation and collagen synthesis — a key mechanism in cardiac fibrosis, pulmonary fibrosis, and renal fibrosis. GHK-Cu (copper peptide GHK) has demonstrated anti-fibrotic properties in several models, including downregulation of TGF-β1 and reduction of collagen III deposition. Combining ET-1 (to drive fibrosis) with GHK-Cu (as a potential anti-fibrotic intervention) creates a model useful for studying fibrosis mechanisms and testing therapeutic candidates.
| Component | Dose | Route | Duration |
|---|---|---|---|
| ET-1 (fibrosis induction) | 1 pmol/kg/min | Osmotic pump SC | 4 weeks |
| GHK-Cu | 1–5 mg/kg | IP injection | Daily, weeks 1–4 |
| Endpoints | Cardiac collagen content, TGF-β1 mRNA, Masson's trichrome staining | — | Week 4 |
---
Safety Deep Dive
Common Effects in Research Models
Researchers working with ET-1 need to understand its safety profile — not for human subjects, but for the experimental animals in their models and for safe laboratory handling.
Cardiovascular effects (dose-dependent):
Acute hypertension:: Nearly universal at doses >0.5 pmol/kg/min IV in rodents. Onset within 60–90 seconds of infusion start. Sustained for 30–90 minutes post-infusion.
Bradycardia:: Often accompanies the pressor response via baroreflex activation. Transient, typically resolving within the infusion period.
Coronary spasm:: Risk increases sharply above 2 pmol/kg/min. ST-segment changes and arrhythmias have been observed in dogs at 3–5 pmol/kg/min intracoronary.
Mesenteric ischemia:: At high systemic doses (>10 pmol/kg/min), splanchnic vasoconstriction can cause bowel ischemia in rodents.
Renal effects:
Dose-dependent reduction in glomerular filtration rate at doses producing MAP increases >20 mmHg
Tubular vacuolization observed histologically after chronic infusion >2 weeks at high doses
Proteinuria develops within 1 week at 2 pmol/kg/min in rats
Pulmonary effects:
Right ventricular pressure increases at doses causing pulmonary vasoconstriction
Chronic ET-1 infusion (>3 weeks) produces pulmonary vascular remodeling in susceptible strains
Rare and Theoretical Risks
Anaphylaxis: Synthetic peptides carry a theoretical risk of immune sensitization. This is uncommon with ET-1 given its small size and endogenous nature, but researchers should monitor for unexpected reactions in large animal models.
Catastrophic coronary spasm: The biggest acute risk in cardiac research models. Always have IV nitroglycerin or isosorbide dinitrate immediately available during ET-1 infusion studies. Never administer ET-1 to animals with pre-existing coronary artery disease models without appropriate precautions.
Cerebral vasospasm: ET-1 injected into the subarachnoid space (used in cerebral vasospasm models) can cause stroke-like lesions if doses exceed 100 nmol. This is intentional in vasospasm models but must be dose-controlled carefully.
ET-1 is not for human administration. This bears explicit statement. ET-1 is not approved for human use as a therapeutic agent. At the doses active in human physiology, exogenous ET-1 administration would cause severe hypertension, potential coronary spasm, and acute kidney injury. All ET-1 research must be conducted under appropriate institutional animal care and biosafety protocols.
Contraindications in Research Models
Do not use ET-1 in animals with pre-existing severe aortic stenosis or hypertrophic cardiomyopathy models — risk of acute cardiac decompensation
Avoid ET-1 in hemorrhagic shock models — the vasoconstriction can mask hemodynamic endpoints
Do not combine with other vasoconstrictors (phenylephrine, vasopressin) at pressor doses without careful hemodynamic monitoring
Animals with single kidney models (uninephrectomy) are especially vulnerable to ET-1-induced acute kidney injury
---
ET-1 Compared to Alternatives
Researchers studying vasoconstriction and vascular biology have several peptide tools available. Here's how ET-1 compares:
| Feature | ET-1 | Angiotensin II | Vasopressin (AVP) | LL-37 (indirect) |
|---|---|---|---|---|
| Primary mechanism | ETA/ETB GPCRs → Ca²⁺/RhoA | AT1R → PLC/PKC | V1aR → Ca²⁺ | Cathelicidin → indirect |
| Vasoconstriction potency | ★★★★★ (most potent known) | ★★★★ | ★★★ | N/A (indirect) |
| Duration of action | 1–2h post-infusion | 5–15 min | 10–30 min | N/A |
| Plasma half-life | 1–2 min | 1–2 min | 5–15 min | ~3h |
| Proliferative effects | Strong (VSMC, fibroblast) | Moderate | Minimal | Anti-proliferative |
| Receptor selectivity | ETA > ETB | AT1 >> AT2 | V1a > V2 | Multiple |
| Renal effects | Vasoconstriction + natriuresis | Sodium retention | Water retention | Antimicrobial |
| Clinical drug target | Yes (bosentan, ambrisentan) | Yes (ARBs, ACE-I) | Yes (tolvaptan) | Investigational |
| Research cost tier | High ($$$$) | Moderate ($$) | Moderate ($$) | High ($$$) |
| In vitro stability | Good (in acidic solution) | Good | Good | Moderate |
| Primary research use | PAH, HTN, fibrosis, pain | HTN, heart failure, renal | Heart failure, hyponatremia | Antimicrobial, immune |
Angiotensin II is often preferred for acute blood pressure studies because it's less expensive, faster to reverse, and has a better-characterized dose-response relationship. ET-1 is the tool of choice when researchers need to study sustained vasoconstriction, vascular remodeling, smooth muscle proliferation, or pulmonary vascular disease — applications where ET-1's unique receptor pharmacology and sustained effects are advantages rather than complications.
Semaglutide and other metabolic peptides interact with ET-1 signaling indirectly: GLP-1 receptor agonism has been shown to reduce ET-1 production in endothelial cells, which may partially explain GLP-1's cardiovascular protective effects. This is an active research area.
---
What's Coming Next: Ongoing Research and Open Questions
ET-1 in Oncology
The endothelin axis has emerged as an oncological target. ET-1 promotes tumor angiogenesis, inhibits apoptosis, and stimulates matrix metalloproteinase production — all processes that support tumor invasion and metastasis. ETA receptors are overexpressed in ovarian, prostate, breast, and colon cancers.
Zibotentan (ZD4054), a selective ETA antagonist, entered Phase III trials for castration-resistant prostate cancer. The ENTHUSE trials ultimately failed to show survival benefit as monotherapy, but combination approaches with chemotherapy are being explored. The key question is whether ET-1 is a driver or a passenger in tumor progression — and whether blocking it at the right disease stage (earlier, in combination) changes outcomes.
Current trials (ClinicalTrials.gov identifiers NCT03337529 and related) are testing ETA antagonists in combination with immunotherapy in solid tumors, based on evidence that ET-1 signaling suppresses anti-tumor immune responses by downregulating MHC class I expression on tumor cells.
Cerebral Vasospasm After Subarachnoid Hemorrhage
ET-1 is the leading candidate mediator of delayed cerebral vasospasm after subarachnoid hemorrhage (SAH) — the dreaded complication that causes stroke in 30% of SAH survivors. Plasma and CSF ET-1 levels spike 3–7 days after SAH, exactly when vasospasm peaks.
Clazosentan, an ETA-selective antagonist, reduced angiographic vasospasm in the CONSCIOUS-1 and CONSCIOUS-2 trials, but didn't improve functional neurological outcomes — suggesting vasospasm is not the only mechanism driving post-SAH brain injury. The question remains: is ET-1 the right target, or is the window of intervention wrong, or are there compensatory mechanisms that blunt clinical benefit even when vasospasm is reduced?
A Japanese Phase II trial of clazosentan (NCT03585270) is testing higher doses and broader patient selection to address these questions.
ET-1 in Scleroderma and Pulmonary Fibrosis
ET-1 is massively overproduced in systemic sclerosis (scleroderma) — plasma levels are 3–5x normal — and drives both pulmonary fibrosis and digital ischemia. Ambrisentan and macitentan are now used clinically for scleroderma-associated PAH. Active research is asking whether ET-1 antagonism can also slow skin and lung fibrosis — not just treat its vascular consequences.
Macitentan (dual ETA/ETB antagonist) showed superior outcomes to bosentan in the SERAPHIN trial (742 PAH patients, 3.5 years), reducing the composite of morbidity/mortality by 45% relative to placebo. This is now the longest-duration ET-1 receptor antagonist trial completed, and its results are reshaping PAH treatment guidelines.
Unanswered Questions
The most pressing questions in ET-1 research right now:
1. Why do ETA antagonists reduce pulmonary vascular resistance but haven't clearly reduced mortality in PAH? Is the benefit real but masked by study design, or does ET-1 become a bystander as disease progresses?
2. What is the physiological function of vascular ETB on smooth muscle cells? Its role appears to be vasoconstriction in some beds and vasodilation in others — the determinants of which effect predominates are not fully characterized.
3. Can ET-1 signaling be targeted in pain medicine without cardiovascular liability? Peripheral ETB agonism (paradoxically) reduces neuropathic pain in some models — could tissue-selective ETB agonists become analgesics?
4. Does the ET-1/ECE-1 axis represent a better target than receptor antagonism? ECE-1 inhibitors would block production of both ET-1 and ET-2/ET-3, potentially providing broader coverage. No ECE-1 inhibitor has advanced to Phase III.
5. How does ET-1 interact with the immune system in inflammatory disease? ET-1 activates macrophages, promotes neutrophil adhesion, and upregulates endothelial adhesion molecules. Whether this inflammatory role is therapeutically targetable in autoimmune vascular disease (e.g., vasculitis) is an open question.
---
Key Takeaways
ET-1 is a 21-amino-acid bicyclic peptide: with two disulfide bonds, making it structurally rigid and responsible for extraordinarily tight receptor binding — Kd in the sub-nanomolar range.
It is the most potent endogenous vasoconstrictor known: , active at picomolar plasma concentrations, producing sustained vasoconstriction lasting hours via the RhoA/ROCK calcium-sensitization pathway.
ETA receptors drive vasoconstriction and proliferation: on vascular smooth muscle; ETB receptors on endothelium drive vasodilation and ET-1 clearance — understanding this distinction is essential for interpreting pharmacological data.
ET-1 is a validated clinical target: — endothelin receptor antagonists (bosentan, ambrisentan, macitentan) are approved first-line therapies for pulmonary arterial hypertension, with demonstrated improvements in exercise capacity and disease progression.
In research models: , ET-1 is used at 0.5–5 pmol/kg/min IV or via osmotic minipump to create reproducible hypertensive and vascular remodeling states.
Extreme purity matters: — ET-1 with incorrectly formed disulfide bonds has dramatically reduced activity. Always request CoA confirming disulfide bond confirmation, not just HPLC percentage.
ET-1 amplifies other vasopressor systems: — it synergizes with angiotensin II and aldosterone, making it particularly relevant to models of resistant hypertension and cardiorenal syndrome.
ET-1 is a pain mediator: — ETB activation on peripheral nociceptors drives mechanical allodynia and thermal hyperalgesia, with implications for cancer pain and ischemic pain states.
Oncology is the next frontier: — ET-1's roles in tumor angiogenesis, immune evasion, and metastasis are being actively explored, with ETA antagonists in combination trials.
ET-1 is not for human self-administration: — it is a research tool whose pharmacological profile makes exogenous administration dangerous at any dose that would be physiologically meaningful.
---
🔬 Explore our peptide database — Browse 500+ research peptide profiles with mechanisms, dosing, and evidence.
🛒 Ready to buy? — Browse our verified vendor shop for third-party tested peptides.
🤖 Have questions? — Ask PeptideAI for personalized peptide guidance.
📚 Want more guides? — Browse all research articles covering peptide science and buying guides.
---